640 results on '"Raje, N"'
Search Results
102. Pim2 is important for regulating DNA damage response in multiple myeloma cells
103. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
104. RADIATION THERAPY AS A BRIDGING AND SALVAGE STRATEGY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA UNDERGOING BCMA‐TARGETED CAR T‐CELL THERAPY.
105. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib
106. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
107. HDAC Inhibition in Multiple Myeloma with a Focus on Selective HDAC6 Inhibition
108. Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM)
109. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
110. Bisphosphonates and Atypical Femoral Fractures
111. Fatty acid synthase is a novel therapeutic target in multiple myeloma
112. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
113. Synthesis of flexible polymeric shielding materials for soft gamma rays: Physicomechanical and attenuation characteristics of radiation crosslinked polydimethylsiloxane/Bi2O3 composites
114. Comparison of Denosumab Vs Zoledronic Acid for Treatment of Bone Disease in Adults with Newly Diagnosed Multiple Myeloma: a Randomized, Double-Blind, Multinational Phase 3 Trial
115. MicroRNA expression patterns in medullary and extramedullary plasmacytoma
116. 14LBA - Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma
117. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
118. Phase Transition of Nanoconfined Water in Clay: Positron Annihilation, Nuclear Magnetic Resonance, and Dielectric Relaxation Studies
119. Synthesis of flexible polymeric shielding materials for soft gamma rays: Physicomechanical and attenuation characteristics of radiation crosslinked polydimethylsiloxane/Bi2O3 composites.
120. Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial
121. Trends In Kansas City Tree Pollen: A 15 Year Perspective
122. Synthesis, Structural Characterization and Thermal Stability of Nanocrystalline Rare-Earth Chromates (RECrO4) and Rare-Earth Chromites (RECrO3)
123. The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM).
124. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
125. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
126. Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
127. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
128. Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM)
129. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
130. Statistical numerical modelling of sub-surface initiated spalling in bearing contacts
131. B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma
132. A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib
133. B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma
134. B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease
135. A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
136. A discrete damage mechanics model for high cycle fatigue in polycrystalline materials subject to rolling contact
137. B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma
138. B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma
139. B357 Targeting Myeloma Bone Disease via Activin A Inhibition
140. B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B
141. Reply to the Letter to the Editor from Noopur Raje and Kenneth C. Anderson
142. The research mission in myeloma
143. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study
144. Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma
145. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
146. Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma
147. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
148. Mo-P4:278 Underutilization of vascular medications following carotid endarterectomy
149. CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM)
150. An Improved Multipurpose Grease For Automotive Applications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.